Τόμος 15 (2001) – Τεύχος 3 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 15 (2001) – Issue 3 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1.       Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, 48 Vas. Constantinou Ave., 11635 Athens, Greece

2.      Laboratory of Biological Chemistry, Medical School, University of Athens, 75 M. Asias str., 11527 Athens, Greece

pharmakonpress[at]pharmakonpress[.]gr

2.    Balmain A., Pragnell I.B.: Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 303: 72-74 (1983)

3.    Quintanilla M., Brown K., Ramsden M., Balmain A.: Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80 (1986)

4.    Brown K., Quintanilla M.p Ramsden M., Kerr I.B., Young S., Balmain A.: v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis. Cell 46: 447-456 (1986)

5.    Bremner R., Balmain A.: Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 1990 61: 407-417 (1990)

6.    Zoumpourlis V., Papassava P., Linardopoulos S., Gillespie D., Balmain A., Pintzas A.: High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 79: 4011-4021 (2000)

7.    Thut C.J., Goodrich J.A., Tjian R.: Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 11: 1974-1986 (1997)

8.    Burns P.A., Kemp C.J., Gannon J.V., Lane D.P., Bremner R., Balmain A.: Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene 6: 2363-2369 (1991)

9.    Bartkova J., Jucas J., Muller H., Lutzhaft D., Strauss M.P Bartek J.: Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57: 353-361 (1994)

10.  Gille H., Downward J.: Multiple ras effector pathways contribute to G(1) ceil cycle progression. J. Biol. Chem. 274: 22033-22040 (1999)

11.  Loughram D.p Edintgon K.G., Berry I.J., Clark L.J., Parkinson E.K.: Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Res. 54: 5045-5049 (1994)

12.  Linardopoulos S., Street A.J., Quell D.E., Parry D., Peters G., Sherr C.J., Balmain A.: Deletion and altered regulation of p16^INKa and p16^INKb in undifferentiated mouse skin tumours. Cancer Res. 55: 5168-5172 (1995)

13.  Schutte J., Viallet J., Nau M., Segal S., Fedorko J., Minna J.: jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell 59, 987-997 (1989)

14.  Vandel L., Montreau N., Vial E., Pfarr C.M., Binetruy B., Castellazzi M.: Stepwise transformation of rat embryo fibroblasts: c-Jun, JunB, or JunD can cooperate with Ras for focus formation, but a c-Jun-containing heterodimer is required for immortalization. Mol. Cell Biol. 16: 1881-1888 (1996)

15.  Suzuki T., Murakami M., Onai N., Fukuda E.p Hashimoto Y., Sonobe M.H., Kameda T., Ichinose M., Miki K., Iba H.: Analysis of AP-1 function in cellular transformation pathways. J. Virol. 68: 3527-3535 (1994)

16.  Kustikova O., Kramerof D., Grigorian M., Berezin V., Bock E., Lukanidin E., Tulchinsky E.: Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of the epitheloid adenocarcinoma cells. Mol. Cell Biol. 18: 7095-70105 (1998)

17.  Greenhalgh D.A., Wang X.J., Eckhardt J.N., Roop D.R.: 12-0-tetradecanoyl-phorbol-13-acetate promotion of transgenic mice expression epidermal-targeted v-fos induces ras HA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy. Cell Growth Dili. 6: 579-586 (1995)

18.  Campbell S.L, KhosraviFar R., Rossman K.L., Clark G.J., Dez C.J.: Oncogene 17: 1395-1413 (1998)

19.  Schwarz J.A., Viaje A., Slaga T.J.: Fluocinolone acetonide: a potent inhibitor of mouse skin tumor promotion and epidermal DNA synthesis. Chem. Biol. Interact. 17: 331-347 (1994)

20.  Slaga T.J.: Can tumour promotion be effectively inhibited? IARC Sci Publ 56, 497-506, 1984. 21. Beato M, Herrlich P, Schütz G. Steroid hormone receptors: many actors in search of a plot. Cell 83: 851-857 (1995)

22.  Wasylyk C., Imler J.L., Wasylyk B.: Transforming but not immortalising oncogenes activate the transcription factor PEA1. EMBOJ. 7: 2475-2483 (1988)

23.  Diamond M.I., Miner J.N., Yoshinaga S.K., Yamamoto K.R.: Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249: 1266-1272(1990)

24.  Göttlicher M., Heck S., Herrlich P.: Transcriptional crosstalk, the second mode of steroid hormone receptor action. J. Mol. Med. 76: 480-9, 1998

25.  Heck S.p Kullmann M., Gast A., Ponta H., Rahmsdorf H.J., Herrlich P., Cato A.C.: A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBOJ. 13: 4087-4095 (1994)

26.  Kamei Y.P Xu L, Heinzei T., Torchia J., Kurokawa R., Gloss B., Lin S.C., Heyman R.A., Rose D.W., Glass C.K., Rosenfeld M.G.A.: CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403-414 (1996)

27.  Caelles C.p Gonzalez-Sancho J.M., Munoz A.: Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 11: 3351-3364 (1997)

28.  Oakley R.H., Cidlowski J.A.: Homologous down regulation of the glucocorticoid receptor: the molecular machinery. Crit. Rev. Eukaryot. Gene Expr. 3: 63-88 (1993)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr